JP2021500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500025A5
JP2021500025A5 JP2020521880A JP2020521880A JP2021500025A5 JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5 JP 2020521880 A JP2020521880 A JP 2020521880A JP 2020521880 A JP2020521880 A JP 2020521880A JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
stands
galnac
nucleotides
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020521880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500025A (ja
JP7353276B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056801 external-priority patent/WO2019079781A2/en
Publication of JP2021500025A publication Critical patent/JP2021500025A/ja
Publication of JP2021500025A5 publication Critical patent/JP2021500025A5/ja
Priority to JP2023151506A priority Critical patent/JP7645323B2/ja
Application granted granted Critical
Publication of JP7353276B2 publication Critical patent/JP7353276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020521880A 2017-10-20 2018-10-19 B型肝炎感染の治療方法 Active JP7353276B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023151506A JP7645323B2 (ja) 2017-10-20 2023-09-19 B型肝炎感染の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575358P 2017-10-20 2017-10-20
US62/575,358 2017-10-20
PCT/US2018/056801 WO2019079781A2 (en) 2017-10-20 2018-10-19 METHODS OF TREATING HEPATITIS B TYPE INFECTIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023151506A Division JP7645323B2 (ja) 2017-10-20 2023-09-19 B型肝炎感染の治療方法

Publications (3)

Publication Number Publication Date
JP2021500025A JP2021500025A (ja) 2021-01-07
JP2021500025A5 true JP2021500025A5 (cg-RX-API-DMAC7.html) 2023-07-21
JP7353276B2 JP7353276B2 (ja) 2023-09-29

Family

ID=66173915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521880A Active JP7353276B2 (ja) 2017-10-20 2018-10-19 B型肝炎感染の治療方法
JP2023151506A Active JP7645323B2 (ja) 2017-10-20 2023-09-19 B型肝炎感染の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023151506A Active JP7645323B2 (ja) 2017-10-20 2023-09-19 B型肝炎感染の治療方法

Country Status (30)

Country Link
US (6) US10799524B2 (cg-RX-API-DMAC7.html)
EP (2) EP3684377B1 (cg-RX-API-DMAC7.html)
JP (2) JP7353276B2 (cg-RX-API-DMAC7.html)
KR (1) KR102783206B1 (cg-RX-API-DMAC7.html)
CN (2) CN118185936A (cg-RX-API-DMAC7.html)
AU (1) AU2018351649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020007476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078960A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001061A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020005135A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200163A (cg-RX-API-DMAC7.html)
DK (1) DK3684377T3 (cg-RX-API-DMAC7.html)
ES (1) ES2936863T3 (cg-RX-API-DMAC7.html)
FI (1) FI3684377T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230023T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061122T2 (cg-RX-API-DMAC7.html)
IL (4) IL274040B2 (cg-RX-API-DMAC7.html)
LT (1) LT3684377T (cg-RX-API-DMAC7.html)
MA (1) MA50264B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004060A (cg-RX-API-DMAC7.html)
MY (1) MY201698A (cg-RX-API-DMAC7.html)
PE (1) PE20220561A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550591A1 (cg-RX-API-DMAC7.html)
PL (1) PL3684377T3 (cg-RX-API-DMAC7.html)
PT (1) PT3684377T (cg-RX-API-DMAC7.html)
RS (1) RS64001B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003488WA (cg-RX-API-DMAC7.html)
SI (1) SI3684377T1 (cg-RX-API-DMAC7.html)
UA (1) UA128786C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019079781A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684377B1 (en) 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
US20220389430A1 (en) * 2019-10-02 2022-12-08 Dicema Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
CN114867856A (zh) * 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
EP4081217A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
EP4081639A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CA3187388A1 (en) * 2020-07-27 2022-02-03 Jin Hong Hbv binding oligonucleotides and methods of use
JP2023536999A (ja) * 2020-08-05 2023-08-30 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎患者のオリゴヌクレオチド処置
KR102798766B1 (ko) * 2020-12-18 2025-04-23 올릭스 주식회사 HBV 발현을 억제하는 RNAi 제제 및 이의 용도
CN114853829A (zh) * 2021-02-05 2022-08-05 上海拓界生物医药科技有限公司 一种核酸配体、其缀合物、制备方法及用途
MX2023012048A (es) * 2021-04-12 2023-10-23 Boehringer Ingelheim Int Composiciones y metodos para inhibir cetohexoquinasa (khk).
CN113171371B (zh) * 2021-04-13 2022-01-25 厦门甘宝利生物医药有限公司 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用
IL307154A (en) * 2021-04-19 2023-11-01 Novo Nordisk As Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
CN117280031A (zh) * 2021-04-19 2023-12-22 诺和诺德股份有限公司 用于抑制核受体亚家族1组h成员3(nr1h3)表达的组合物和方法
AU2022384619A1 (en) 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
KR20240111795A (ko) * 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
EP4201947A1 (en) 2021-12-22 2023-06-28 F. Hoffmann-La Roche AG Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
US20240309383A1 (en) * 2023-02-24 2024-09-19 Suzhou Sanegene Bio Inc. Small interfering rna targeting hbv and uses thereof
WO2025199466A1 (en) 2024-03-22 2025-09-25 Purdue Research Foundation Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
ATE281838T1 (de) 2001-05-04 2004-11-15 Technologie Integrale Ltd Anti-virales reagens
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
DK2094086T3 (da) * 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
CN101755049B (zh) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 初级微rna表达盒
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
RU2745848C2 (ru) * 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
PT2726613T (pt) * 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
US9850486B2 (en) * 2012-12-14 2017-12-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
CN103333890B (zh) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
TWI769565B (zh) * 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US10689647B2 (en) * 2015-05-08 2020-06-23 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
CA3013683C (en) 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
EP3684377B1 (en) 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
JP2023536999A (ja) 2020-08-05 2023-08-30 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎患者のオリゴヌクレオチド処置

Similar Documents

Publication Publication Date Title
JP2020536587A5 (cg-RX-API-DMAC7.html)
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US12303525B2 (en) Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
TW202031267A (zh) S-抗原運輸抑制寡核苷酸聚合物及方法
US20230119360A1 (en) Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
AU2017326372B2 (en) Modified oligonucleotides and methods of use
CN111372593A (zh) 治疗乙型肝炎感染的方法
JP2022551269A5 (cg-RX-API-DMAC7.html)
KR20220148241A (ko) Pd-l1을 표적화하기 위한 방법 및 조성물
TW202126809A (zh) 具有最小氟含量之小干擾rna的化學修飾
JP2023550061A (ja) オリゴヌクレオチド及びその抗b型肝炎とd型肝炎ウイルスにおける応用
JP2022517742A5 (cg-RX-API-DMAC7.html)
KR20240101580A (ko) Hbv 치료를 위한 약학 조합물
JP2022520653A5 (cg-RX-API-DMAC7.html)
TW202237189A (zh) 具有增強之肝靶向的s抗原運輸抑制寡核苷酸聚合物之接合物
WO2025232886A1 (zh) 一种抑制乙型肝炎病毒的寡核苷酸、缀合物、组合物及其用途
WO2021130270A1 (en) Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CN119662639A (zh) 抑制乙型肝炎病毒基因表达的siRNA、其缀合物和药物组合物及用途
HK1077503A1 (zh) 基於核酸的化合物及其使用方法
HK1077503B (en) Nucleic acid-based compounds and methods of use thereof